Mcrae has agreed to step down
from his role as CEO.
But the company also told shareholders that a PP at these levels would be extremely detrimental to shareholders, and then proceeded with the share issue to ensure their tenure in power.
So, knowing what we know about the chameleon-like, self serving behaviour of this management team and BOD, I would expect that they and their "new" votes will win in November.
With that perceived, yet wholly conspicuous mandate, Graeme McRae will continue to oversee the extreme wasting of "our" proceeds from the AH sale.
Funny, actually laughable if you weren't a shareholder, how the same team that can't get a penny of value recognized in their core cancer drug or brand new VMC are so adept at playing the extreme ends of corporate ethics and fiduciary responsibility, to stay in power.
Bring your preferred lubricant.